share_log

Today's biggest pre-market stock movers: MDRR, XERS, ISIG and more

Benzinga Real-time News ·  Dec 31, 2021 08:40  · Markets

Gainers

  • $Medalist Diversified REIT Inc(MDRR.US)$ rose 28.43% to $1.31 in pre-market trading after the company reported a stock repurchase program of 500,000 shares.

  • $Xeris Pharmaceuticals(XERS.US)$ rose 25.51% to $3.05 in pre-market trading as the company reported the FDA approval of Recorlev for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

  • $Insignia Systems(ISIG.US)$ rose 15.12% to $27.34 in pre-market trading after gaining 3% on Thursday.

  • $Biofrontera(BFRI.US)$ rose 9.02% to $8.22 in pre-market trading. Biofrontera announced reduction of Biofrontera AG shareholding to less than 50% through warrant exercises.

  • $Planet Green(PLAG.US)$ rose 8% to $1.08 in pre-market trading. Planet Green recently entered into share exchange agreement with Shandong Yunchu Supply Chain.

  • $Inspira Technologies Oxy(IINN.US)$ rose 6.69% to $5.10 in pre-market trading after jumping more than 27% on Thursday.

  • $Eros STX(ESGC.US)$ rose 6.25% to $0.255 in pre-market trading.

Losers

  • $Star Equity(STRR.US)$ fell 7.6% to $2.81 in pre-market trading. Star Equity Holdings recently named Richard Coleman as COO.

  • $Integrated Media Technology(IMTE.US)$ fell 7.1% to $4.70 in pre-market trading. Integrated Media Technology recently reported launching of NFT trading platform.

  • $Flotek Industries(FTK.US)$ shares fell 6.8% to $1.10 in pre-market trading. Flotek Industries recently said it received an unsolicited indication of interest for a potential transaction for all or part of the company. Flotek's Board of Directors has engaged Piper Sandler & Co.

  • $OceanPal(OP.US)$ fell 6.1% to $2.00 in pre-market trading after gaining around 10% on Thursday.

  • $Spruce Biosciences(SPRB.US)$ shares fell 3.19% to $4.86 in pre-market trading after jumping 17% on Thursday. Oppenheimer recently initiated coverage on the stock with an Outperform rating and a $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment